Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review

Proskuriakova, Ekaterina; Khedr, Anwar

doi:10.7759/cureus.26233

Cited by 5 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In ICC, local expansion of the tumor cells from the primary tumor into the nearby lymphatics through penetration may be the primary driver of tumor-associated angiogenesis [15]. Common growth factors, including vascular endothelial growth factor (VEGF-C), which were overexpressed in both tumor types, can be secreted by both prostate cancer and ICC, and encourage lymph angiogenesis [16]. Hence, autocrine modulation of lymphangiogenic growth factors may enhance metastasis.…”

Section: Discussionmentioning

confidence: 99%

A Case of Prostatic Metastasis from Intrahepatic Cholangiocarcinoma: An Extremely Rare Event

Aiyadurai¹,

Garg²,

Sayeed³

et al. 2023

Cureus

View full text Add to dashboard Cite

The second most frequent primary carcinoma of the liver to emerge is intrahepatic cholangiocarcinoma (ICC), which is thought to be an incurable, rapidly proliferating tumor with a dismal prognosis. ICC is typically found at an advanced stage and is physiologically hostile. Regional lymph nodes and liver metastases are frequent tumor metastatic sites for ICC and serve as indicators of tumor recurrence. ICC metastasizing to the male urogenital tract has only seldom been documented. Typically, lymph vessels serve as the primary pathway for disseminating tumor cells. The high fatality rate associated with ICC and the rapid spread of the disease may be caused by this lymphatic route. The only curative therapeutic approach for treating these tumors is surgical removal. We report a case of prostatic metastasis from ICC.

show abstract

Section: Discussionmentioning

confidence: 99%

A Case of Prostatic Metastasis from Intrahepatic Cholangiocarcinoma: An Extremely Rare Event

Aiyadurai¹,

Garg²,

Sayeed³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…With the evolution in understanding of the molecular heterogeneity of CCA, several targeted therapies have been proposed and shown promising antitumour activities. 33 Pemigatinib is the first approved targeted therapy for locally advanced or metastatic CCA with FGFR2 fusions or rearrangement.…”

Section: Discussionmentioning

confidence: 99%

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases

Wadsley¹,

Christie²,

Gillmore³

et al. 2023

DIC

View full text Add to dashboard Cite

The management of advanced cholangiocarcinoma (CCA) is challenging. In patients with advanced CCA, gemcitabine/cisplatin combination is the standard frontline chemotherapy, with 5-fluorouracil-based regimens preserved for subsequent lines; however, the expected survival is poor. Pemigatinib was approved for locally advanced or metastatic CCA with FGFR2 fusions or rearrangement. Pemigatinib has a manageable safety profile and achieves a durable response. Nearly 50 patients with CCA have been treated with pemigatinib in the United Kingdom. However, clinical experience with pemigatinib is lacking. We present our experience with three clinical cases to illustrate the position of pemigatinib in the management of CCA and related toxicities.

show abstract

“…Surprisingly, treatment of KKU-M213 cells with a concentration 4.67 µM-fold lower than the IC 50 of (±)-ARC showed strong suppression of its target proteins, including HSP90α and PI3K, with regulated cell proliferation (Figure 8C). Target proteins for CCA treatment have been reported, such as FGFR, IDH1, HER2, NTRK, PI3K, and MAPK [3,20]. The drugs in a clinical study for targeted therapies with FDA approval, including pemigatinib, ivosidenib, zanidatamab, and futibatinib, which target FGFR, IDH1, HER2, and FGFR, respectively [3].…”

Section: Discussionmentioning

confidence: 99%

Trans-(±)-TTPG-B Attenuates Cell Cycle Progression and Inhibits Cell Proliferation on Cholangiocarcinoma Cells

Rattanaburee,

Chompunud Na Ayudhya,

Thongpanchang

et al. 2023

Molecules

View full text Add to dashboard Cite

This research aimed to determine the target protein and molecular mechanism of trans-(±)-kusunokinin ((±)-KU) derivatives (trans-(±)-ARC and trans-(±)-TTPG-B). Molecular docking was used to predict potential synthesized (±)-KU targets among 22 proteins. The (±)-TTPG-B bound HSP90α better than EC44, native (±)-KU and (-)-KU, and (±)-KU and (−)-ARC. In contrast, (−)-ARC bound PI3K more strongly than any other test compound. CSF1R and AKR1B1 were not supposed to be the target of (±)-TTPG-B and (±)-ARC, unlike native (±)-KU. The (±)-TTPG-B bound Tyr139 and Trp162 of HSP90α. Moreover, (−)-ARC bound PI3K via hydrogen bonds and π-π stacking at distinct amino acids, which was different from the other tested compounds. Using half of the IC50 concentration, (±)-TTPG-B, (±)-KU and (±)-ARC enhanced cell cycle arrest at the G0/G1 phase after 12 h and 24 h on KKU-M213 (CCA) cells. The (±)-TTPG-B showed a stronger inhibitory effect than (±)-ARC and (±)-KU on HSP90α, PI3K, HSP90β, c-Myc, AKT, MEK1, CyclinB1, CyclinD1, and CDK1 for 24 and 48 h after treatment with the same concentration (0.015 µM). Thus, trans-(±)-TTPG-B, a newly synthesized compound, has pharmacological potential for development as a target therapy for CCA treatment.

show abstract

Current Targeted Therapy Options in the Treatment of Cholangiocarcinoma: A Literature Review

Cited by 5 publications

References 53 publications

A Case of Prostatic Metastasis from Intrahepatic Cholangiocarcinoma: An Extremely Rare Event

A Case of Prostatic Metastasis from Intrahepatic Cholangiocarcinoma: An Extremely Rare Event

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases

Trans-(±)-TTPG-B Attenuates Cell Cycle Progression and Inhibits Cell Proliferation on Cholangiocarcinoma Cells

Contact Info

Product

Resources

About